ProLung Shareholder Group Receives More Than The Requisite Number Of Consents To Enlarge And Enhance The Board

SALT LAKE CITY, Sept. 28, 2018 /PRNewswire/ -- The shareholder group led by Steve Eror (the "Shareholder Group"), the Co-Founder and Former CEO of ProLung, Inc. ("ProLung" or, the "Company"), which collectively owns approximately 16.3% of the Company's outstanding common stock, announced today that it is gratified to have received consents to enlarge the size of ProLung's Board of Directors (the "Board") to 13 members and elect its eight director nominees to the Board.  The Shareholder Group's proposals will not take effect until it formally delivers the package with the consents it has received to the Company, which it expects to do next week. 

Mr. Eror issued the following statement on behalf of the Shareholder Group:

"We greatly appreciate the strong shareholder support we have received to date, which validates our belief that significant changes to the composition of the Board are gravely needed at this critical juncture for ProLung.  Despite the Company's efforts to unfairly block our legitimate consent solicitation, including the Board's refusal to make available to us a list of the Company's shareholders, we have nonetheless collected consents from shareholders owning more than 50% of the Company's outstanding shares.  We believe the election of our slate of eight directors will be an important step toward restoring and maximizing shareholder value and to properly address the significant issues facing ProLung. 

Despite ProLung's attempts to scare shareholders about our intentions with regard to the Company, shareholders can be assured that our director slate is committed to acting in the best interests of shareholders in accordance with their fiduciary duties and are squarely focused on maximizing value for all shareholders.  We would caution the Board against seeking to undertake any material activities or changes during the pendency of our consent delivery process or any further attempts to unfairly impede our legitimate consent process."

About Steve Eror
Mr. Eror has 26 years of executive experience in medical device, drug development, drug delivery, molecular modeling, artificial intelligence, biopharmaceuticals, diagnostics, information technology and manufacturing in public, private and emerging companies.  He is ProLung's co-founder, and served as the Company's CEO, President and Board member from February 2005 until June 2018.

Investor Contact
Steven C. Eror
(801) 631-7288
Enlargeandenhance@yahoo.com

View original content:http://www.prnewswire.com/news-releases/prolung-shareholder-group-receives-more-than-the-requisite-number-of-consents-to-enlarge-and-enhance-the-board-300721240.html

SOURCE Steve Eror